Regeneron Pharmaceuticals' Free Cash Flow rose 35.07% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 22.73%. This contributed to the annual value of $3.7 billion for FY2024, which is 5.44% down from last year.
Latest data reveals that Regeneron Pharmaceuticals reported Free Cash Flow of $1.4 billion as of Q3 2025, which was up 53.16% from $925.4 million recorded in Q2 2025.
In the past 5 years, Regeneron Pharmaceuticals' Free Cash Flow registered a high of $3.3 billion during Q3 2021, and its lowest value of $173.5 million during Q2 2024.
Moreover, its 3-year median value for Free Cash Flow was $938.3 million (2023), whereas its average is $972.6 million.
Per our database at Business Quant, Regeneron Pharmaceuticals' Free Cash Flow skyrocketed by 905.01% in 2021 and then plummeted by 85.17% in 2022.
Over the past 5 years, Regeneron Pharmaceuticals' Free Cash Flow (Quarterly) stood at $2.2 billion in 2021, then dropped by 29.31% to $1.6 billion in 2022, then crashed by 46.53% to $838.3 million in 2023, then increased by 26.83% to $1.1 billion in 2024, then surged by 35.07% to $1.4 billion in 2025.
Its last three reported values are $1.4 billion in Q3 2025, $925.4 million for Q2 2025, and $815.8 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value